ClinicalTrials.gg
RecruitingNCT04908319Updated Jul 20, 2025

Hepatic Histopathology in Urea Cycle Disorders

An observational study in Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency and Citrullinemia 1, sponsored by Baylor College of Medicine. Recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2025-07-20.

Primary conditionOrnithine Carbamoyltransferase Deficiency DiseaseRegistry: Urea Cycle Disorders, InbornReclassifiedWhy we changed it
Registry
Urea Cycle Disorders, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ornithine Carbamoyltransferase Deficiency Disease
Why
  1. The study's listed conditions name Ornithine Carbamoyltransferase Deficiency Disease, a narrower term within Urea Cycle Disorders, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Baylor College of Medicine · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
70
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.

Planned enrollment
8th of 16
70 · median 66
Started
2022
with 1 other
Observational
16 of 28
5 open now
Primary completion
2026-06
later than 0 of 10 live
Registered
23rd of 28
by date
Lead sponsor
2 of 28
Baylor College of Medicine

Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 8th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2022, is one of 16 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 23rd registered.

Ornithine Carbamoyltransferase Deficiency Disease

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Open to participants now

6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any UCD diagnosis. This study will be conducted at all Urea Cycle Disorders Consortium (UCDC) sites: Baylor College of Medicine in Houston, TX and Children's National Medical Center in Washington D.C.

Read the detailed description

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this improved survival has led to unmasking of some long-term complications such as hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications in UCDs are quite variable and dependent upon the specific metabolic defect.

03

Conditions studied

  • Urea Cycle Disorder
  • Ornithine Transcarbamylase Deficiency
  • Citrullinemia 1
  • ARGI Deficiency
  • ASL Deficiency
  • Argininosuccinic Aciduria
  • ASS Deficiency
  • Hyperargininemia
  • Carbamyl Phosphate Synthetase Deficiency
  • NAGS Deficiency

Keywords

  • Liver transplant
  • Liver disease
  • Liver biopsy
  • Histopathology
04

In context

Ornithine Carbamoyltransferase Deficiency Disease Reclassified

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

This study's planned enrollment of 70 is close to the median of 70 across 28 observational studies indexed under Ornithine Carbamoyltransferase Deficiency Disease.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 110 are open to participants now.

Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.

Compared within Ornithine Carbamoyltransferase Deficiency Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urea Cycle Disorders, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with urea cycle disorders

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary urea cycle disorder based on clinical suspicion confirmed by enzyme activity, DNA testing or metabolite analysis.
  • History of liver transplantation and/or liver OR
  • Planned liver transplantation and/or liver biopsy

Exclusion criteria

Exclusion Criteria:

  • Unavailability of histopathology report from the liver or explant, or unavailability of liver tissue or slides from the biopsy or explant OR
  • Anticipated inability to obtain pathology report, liver disease, tissue blocks, or pathology slides after liver biopsy or transplantation
  • Known history of a secondary cause for liver disease such as chronic viral hepatitis, liver disease, short gut, small bowel syndrome, alcohol liver disease, or TPN-related cholestatic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
70 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
07

What researchers measure

Primary outcomes

  1. Hepatic fibrosis

    Staging of fibrosis from histopathology report from the liver biopsy or explant

    Time frame: Day 1

  2. Steatosis

    Grade of steatosis from histopathology report from the liver biopsy or explant

    Time frame: Day 1

  3. Hepatic glycogenosis

    Presence and type of glycogenosis from histopathology report from the liver biopsy or explant

    Time frame: Day 1

08

Study locations

1 of 2 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jun 2026, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
Jun 1, 2021
StartActual
Feb 24, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04908319
Responsible party
Lindsay Burrage (Principal Investigator, Baylor College of Medicine) — Principal investigator
First posted
Jun 1, 2021
Start date
Feb 24, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jul 20, 2025

Study contacts

Saima Ali, MSN
Contact
saima.ali@bcm.edu
832-822-4183
Lindsay Burrage, MD, PhD
principal investigator · Baylor College of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion